• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伴有肝转移的治疗难治性、去势抵抗性前列腺癌:一种有前景的治疗方式。

Treatment-Refractory, Castration-Resistant Prostate Cancer With Liver Metastasis: A Promising Modality of Therapy.

作者信息

Findakly Dawood, Duong Tony, Shimon Tim, Wang Jue

机构信息

Hematology and Medical Oncology, Feist-Weiller Cancer Center, Louisiana State University Health Shreveport, Shreveport, USA.

Internal Medicine, University of Arizona College of Medicine, Phoenix, USA.

出版信息

Cureus. 2022 Jul 15;14(7):e26881. doi: 10.7759/cureus.26881. eCollection 2022 Jul.

DOI:10.7759/cureus.26881
PMID:35978760
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9375954/
Abstract

Although significant advances in the treatment of prostate cancer (PC) have recently been made, the treatment of metastatic liver disease remains challenging. Recent advances have led to multiple novel therapies and multi-treatment approaches combining systemic and locoregional modalities, such as thermal ablation, representing a promising strategy that has received attention in recent years. Nevertheless, no standard locoregional treatment regimens exist for the management of liver metastases of PC. In addition, regional therapy alone is unlikely to provide durable cancer control. Here, we report for the first time a successful treatment of hepatic metastases of PC using stereotactic image-guided percutaneous microwave ablation and the poly (ADP-ribose) polymerase-1 inhibitor, olaparib.

摘要

尽管近年来前列腺癌(PC)的治疗取得了重大进展,但转移性肝病的治疗仍然具有挑战性。最近的进展带来了多种新型疗法以及将全身和局部区域治疗方式相结合的多治疗方法,例如热消融,这是一种近年来受到关注的有前景的策略。然而,目前尚无用于管理PC肝转移的标准局部区域治疗方案。此外,单纯的区域治疗不太可能实现持久的癌症控制。在此,我们首次报告了使用立体定向图像引导经皮微波消融和聚(ADP-核糖)聚合酶-1抑制剂奥拉帕尼成功治疗PC肝转移的病例。

相似文献

1
Treatment-Refractory, Castration-Resistant Prostate Cancer With Liver Metastasis: A Promising Modality of Therapy.伴有肝转移的治疗难治性、去势抵抗性前列腺癌:一种有前景的治疗方式。
Cureus. 2022 Jul 15;14(7):e26881. doi: 10.7759/cureus.26881. eCollection 2022 Jul.
2
A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.奥拉帕利治疗转移性去势抵抗性前列腺癌的新用途。
Pharmacotherapy. 2017 Nov;37(11):1406-1414. doi: 10.1002/phar.2027.
3
Successful case of olaparib treatment for castration-resistant prostate cancer with multiple DNA repair gene mutations: Use of comprehensive genome profiling for treatment-refractory cases.奥拉帕利治疗多DNA修复基因突变的去势抵抗性前列腺癌成功病例:难治性病例的综合基因组分析应用
Urol Case Rep. 2022 Aug 30;45:102210. doi: 10.1016/j.eucr.2022.102210. eCollection 2022 Nov.
4
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.奥拉帕利联合阿比特龙治疗转移性去势抵抗性前列腺癌患者的随机、双盲、安慰剂对照、2 期临床试验。
Lancet Oncol. 2018 Jul;19(7):975-986. doi: 10.1016/S1470-2045(18)30365-6. Epub 2018 Jun 4.
5
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.局部晚期和转移性前列腺癌的系统治疗进展:精准肿瘤学时代下转移性去势抵抗性前列腺癌的管理。
Eur Urol. 2019 Jan;75(1):88-99. doi: 10.1016/j.eururo.2018.03.028. Epub 2018 Apr 16.
6
Recent Advances in the Management of Metastatic Prostate Cancer.转移性前列腺癌的治疗进展。
JCO Oncol Pract. 2022 Jan;18(1):45-55. doi: 10.1200/OP.21.00206. Epub 2021 Sep 2.
7
Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancer.聚(ADP - 核糖)聚合酶抑制剂在前列腺癌中的相关性。
Curr Opin Support Palliat Care. 2018 Sep;12(3):339-343. doi: 10.1097/SPC.0000000000000358.
8
Feasibility of Controlling Metastatic Osseous Pain Using Three Kinds of Image-Guided Procedures for Thermal Microwave Ablation: A Retrospective Study.三种影像引导热微波消融术控制转移性骨痛的可行性:回顾性研究。
Orthop Surg. 2021 Feb;13(1):116-125. doi: 10.1111/os.12849. Epub 2020 Dec 10.
9
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.Talazoparib 单药治疗伴有 DNA 修复改变的转移性去势抵抗性前列腺癌(TALAPRO-1):一项开放标签、2 期临床试验。
Lancet Oncol. 2021 Sep;22(9):1250-1264. doi: 10.1016/S1470-2045(21)00376-4. Epub 2021 Aug 10.
10
Recent Development and Future Prospects of Molecular Targeted Therapy in Prostate Cancer.前列腺癌分子靶向治疗的最新进展与未来展望
Curr Mol Pharmacol. 2022;15(1):159-169. doi: 10.2174/1874467214666210608141102.

引用本文的文献

1
Prostate Cancer Liver Metastasis: An Ominous Metastatic Site in Need of Distinct Management Strategies.前列腺癌肝转移:一个需要独特管理策略的凶险转移部位。
J Clin Med. 2024 Jan 27;13(3):734. doi: 10.3390/jcm13030734.
2
A New Immunotherapy Combination Promises to Improve Survival for Patients with Metastatic Prostate Cancer.一种新的免疫疗法组合有望提高转移性前列腺癌患者的生存率。
Cancers (Basel). 2023 Nov 29;15(23):5640. doi: 10.3390/cancers15235640.

本文引用的文献

1
Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study.卡巴他赛治疗转移性去势抵抗性前列腺癌(mCRPC)起始时的疼痛进展:PROSELICA研究的事后分析
Cancers (Basel). 2021 Mar 13;13(6):1284. doi: 10.3390/cancers13061284.
2
Molecular Profiling of Docetaxel-Resistant Prostate Cancer Cells Identifies Multiple Mechanisms of Therapeutic Resistance.多西他赛耐药前列腺癌细胞的分子图谱鉴定出多种治疗耐药机制。
Cancers (Basel). 2021 Mar 14;13(6):1290. doi: 10.3390/cancers13061290.
3
PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date.
PARP抑制剂在转移性前列腺癌中的应用:迄今的证据
Cancer Manag Res. 2020 Sep 7;12:8105-8114. doi: 10.2147/CMAR.S227033. eCollection 2020.
4
Olaparib for Metastatic Castration-Resistant Prostate Cancer.奥拉帕利治疗转移性去势抵抗性前列腺癌。
N Engl J Med. 2020 May 28;382(22):2091-2102. doi: 10.1056/NEJMoa1911440. Epub 2020 Apr 28.
5
Prostate Cancer and Bone Metastases: The Underlying Mechanisms.前列腺癌与骨转移:潜在机制。
Int J Mol Sci. 2019 May 27;20(10):2587. doi: 10.3390/ijms20102587.
6
Precision medicine applications in prostate cancer.精准医学在前列腺癌中的应用。
Ther Adv Med Oncol. 2018 Jun 18;10:1758835918776920. doi: 10.1177/1758835918776920. eCollection 2018.
7
Liver Metastases in Prostate Carcinoma Represent a Relatively Aggressive Subtype Refractory to Hormonal Therapy and Short-Duration Response to Docetaxel Monotherapy.前列腺癌肝转移代表一种相对侵袭性的亚型,对激素治疗耐药,对多西他赛单药治疗反应持续时间短。
World J Oncol. 2015 Feb;6(1):265-269. doi: 10.14740/wjon903w. Epub 2015 Feb 14.
8
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.评估转移部位对去势抵抗性前列腺癌男性患者总生存期影响的Meta分析
J Clin Oncol. 2016 May 10;34(14):1652-9. doi: 10.1200/JCO.2015.65.7270. Epub 2016 Mar 7.
9
Clinical characteristics and prognostic factors of prostate cancer with liver metastases.前列腺癌肝转移的临床特征及预后因素
Tumour Biol. 2014 Jan;35(1):595-601. doi: 10.1007/s13277-013-1083-6.